Citations 2
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
Espinel‐Ingroff, Ana , Carver, Peggy L. , Chen, S. C.-A., Eschenauer, Gregory , Getsinger, Diane, Govender, Nelesh P. , Grancini, Anna, Kidd, Sarah , Klinker, Kenneth , Kubin, Christine J. , Morris, Arthur J. , Peláez, Teresa, Quindós, Guillermo , Sánchez, F , Wengenack, Nancy L. , Solé, N. Borrell, Echeverría, J. , Esperalba, Juliana , Pedrosa, E. Gómez-G. de la, Linares, María José Pedraja, Marco, Francesc , Merino, Paloma , Pemán, Javier , Molino, Luisa Pérez del, Mayans, E. Roselló, Calvo, Carmen Rubio, Pipaón, Maite Ruiz Pérez de, Yagüe, Genoveva, García‐Effrón, Guillermo , Guinea, Jesús , Perlin, David S. , Sanguinetti, Maurizio , Shields, Ryan K. , Turnidge, John , Govender, N P , Quindós, G , Guinea, J , Álvarez-Fernández, Maximiliano , Cantón, Rafael , Chen, S. C.- A., González, Gloria María , Hanson, Kimberly E. , Kus, Julianne V. , Lockhart, Shawn R. , Meletiadis, Joseph , Rodríguez‐Iglesias, Manuel , Shoham, Shmuel , Pedrosa, Elia Gómez G. de la , García, Inmaculada García , Sánchez-Reus, F , Sanguinetti, M , Peman, J , Kidd, Sarah E
Antimicrobial Agents and Chemotherapy | August 18, 2015 | Volume: 59 | Issue: 11 | Pages: 6725-6732
ABSTRACTNeither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established forCandidaspp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable.Candidaspecies wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007Candida albicans, 186C. dubliniensis, 3,188C. glabratacomplex, 119C. guilliermondii, 493C. krusei, 205C. lusitaniae, 3,136C. parapsilosiscomplex, and 1,016C. tropicalisisolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 μg/ml forC. albicans, 0.12, 0.25, and 0.03 μg/ml forC. glabratacomplex, 4, 2, and 4 μg/ml forC. parapsilosiscomplex, 0.5, 0.25, and 0.06 μg/ml forC. tropicalis, 0.25, 1, and 0.25 μg/ml forC. krusei, 0.25, 1, and 0.12 μg/ml forC. lusitaniae, 4, 2, and 2 μg/ml forC. guilliermondii, and 0.25, 0.25, and 0.12 μg/ml forC. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81Candidaisolates with identifiedfksmutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities ofCandidaspp. to caspofungin by reference methodologies is not recommended.
Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia
Yu, Victor L. , Klugman, Keith P. , Örtqvist, Åke, Rello, Jordi , Morris, Arthur J., Luna, Carlos M. , Snydman, David R. , Ko, Wen‐Chien , Chedid, Maria Bernadete Fernandes, Hui, David S.C. , Andremont, Antoine , Chiou, Christine C., Morris, Arthur J. , Baddour, Larry M. , Feldman, Charles , Snydman, D R
American Journal of Respiratory and Critical Care Medicine | June 7, 2004 | Volume: 170 | Issue: 4 | Pages: 440-444
Abstract Retrospective studies have suggested that combination antibiotic therapy for severe bacteremic pneumococcal pneumonia may reduce mortality. We assessed this issue in a prospective, multicenter, international observational study of 844 adult patients with bacteremia due to Streptococcus pneumoniae. The effect of combination antibiotic therapy versus monotherapy on mortality was examined by univariate analyses and by logistic regression models. The 14-day mortality was not significantly different for the two groups. However, among critically ill patients, combination antibiotic therapy was associated with lower 14-day mortality (23.4 versus 55.3%, p = 0.0015). This improvement in survival was independent of country of origin, intensive care unit support, class of antibiotics, or in vitro activity of the antibiotics prescribed. Combination antibiotic therapy improved survival among critically ill patients with bacteremic pneumococcal illness.